<DOC>
	<DOC>NCT01019408</DOC>
	<brief_summary>The purpose of this study was to provide stronger evidence for extended-dose chloroquine treatment of falciparum-positive Afghan refugees in Northwest Frontier Province (NWFP), Pakistan or justification for discontinuation of the policy.</brief_summary>
	<brief_title>Extended-dose Chloroquine (ECQ) for Resistant Falciparum Malaria Among Afghan Refugees in Pakistan</brief_title>
	<detailed_description>To determine whether extended-dose chloroquine provided better cure rates and fewer recrudescences than standard chloroquine treatment among Afghan refugees, 163 falciparum patients from three Afghan refugee camps were recruited into 3-day (CQ 25mg/kg) or 5-day (CQ 40mg/kg) treatment arms and followed for up to 60 days.</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria, Falciparum</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<criteria>slideconfirmed infection with P. falciparum only initial parasite density of 1000100,000 asexual parasites/μl absence of severe malnutrition ability to attend stipulated followup visits and easy access to facility informed consent provided by patient or parent/guardian absence of history of hypersensitivity reactions to CQ infants under six months old pregnancy or lactation underlying chronic severe illness patients with other febrile illnesses parasitaemia outside the range of 1000100,000 asexual parasites/µl severe malaria</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Clinical Trial</keyword>
	<keyword>Chloroquine</keyword>
	<keyword>Refugees</keyword>
	<keyword>Afghanistan</keyword>
	<keyword>Pakistan</keyword>
</DOC>